Literature DB >> 12662207

Ultrafiltration and dry weight-what are the cardiovascular effects?

Bernd G Stegmayr1.   

Abstract

Long-term prognosis in dialysis is poor compared to that in healthy control persons. A worsening of the prognosis is noted especially for patients who at initiation of dialysis have congestive heart failure, ischemic heart disease, or left ventricular dysfunction or hypertrophy. This is the main reason that cardiovascular causes are the most common for morbidity in these patients. The weight obtained when normal urine output is present is the dry weight. With reduced ability to excrete the volume by the kidneys in end-stage renal disease (ESRD), the body will retain water and the patient will gain weight. This extra weight is due to volume overload. While volume overload may induce a rise in blood pressure, if the heart is in acceptable condition, a fast removal of fluid by ultrafiltration (UF) during dialysis may instead cause hypotension. Ultrafiltration failure in peritoneal dialysis (PD) patients may lead to successive water retention and overhydration with subsequent cardiac failure, while volume overload may occur over a few days in hemodialysis (HD) patients. Anemia or even too-high hematocrit may impair cardiac function further and worsen conditions caused by wrong dry weight. Thus, during long-term and sustained volume overload, left ventricular (LV) hypertrophy will occur in an eccentric manner. A sustained overload then may lead to cell death and LV dilatation and, eventually, systolic dysfunction. Once a severe left ventricular dilatation has developed, the blood pressure may decrease during volume overload. A worsened prognosis is seen if malnutrition and low albumin levels are present. Volume overload necessitates ultrafiltration to achieve dry weight. Thereby, volume contraction contributes to exaggerated stimulation of or response to activation of the RAS and alpha-adrenergic sympathetic systems. If ultrafiltration goes beyond these compensatory mechanisms, hypotension will occur and increase the risk for hypoperfusion of vital organs. Such episodes may cause cardiac morbidity, aspiration pneumonia, vascular access closure, or neurological complications (seizures, cerebral infarction), besides a more rapid lowering of residual renal function. Preventive measures are, first, finding the right dry weight; second, minimizing interdialytic weight gain; third, optimizing the target for hemoglobin (110-120 g/l); fourth, lowering dialysate calcium (1.25 mmol/l); and fifth, eventually using higher dialysate potassium if long dialyses are performed.

Entities:  

Mesh:

Year:  2003        PMID: 12662207     DOI: 10.1046/j.1525-1594.2003.07205.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  7 in total

1.  Cardiorenal syndrome type 4: a review.

Authors:  Anna Clementi; Grazia Maria Virzì; Ching Yan Goh; Dinna N Cruz; Antonio Granata; Girogio Vescovo; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2013-04       Impact factor: 2.041

2.  The value of sequential dialysis, mannitol and midodrine in managing children prone to dialysis failure.

Authors:  Daljit K Hothi; Elizabeth Harvey; Cristina M Goia; Denis Geary
Journal:  Pediatr Nephrol       Date:  2009-03-18       Impact factor: 3.714

3.  Long-term efficacy of intermittent peritoneal dialysis using various doses.

Authors:  Zhi-Yong Zhang; Chun-Hua Zhou; Ming-Xu Li; Yong-Wu Yu
Journal:  Exp Ther Med       Date:  2011-12-30       Impact factor: 2.447

4.  Evaluating methods for improving ultrafiltration in pediatric hemodialysis.

Authors:  Daljit K Hothi; Elizabeth Harvey; Cristina M Goia; Denis F Geary
Journal:  Pediatr Nephrol       Date:  2008-01-23       Impact factor: 3.714

5.  Association between ratio of measured extracellular volume to expected body fluid volume and renal outcomes in patients with chronic kidney disease: a retrospective single-center cohort study.

Authors:  Reibin Tai; Yasushi Ohashi; Sonoo Mizuiri; Atsushi Aikawa; Ken Sakai
Journal:  BMC Nephrol       Date:  2014-12-01       Impact factor: 2.388

6.  Hypervolemia-Induced Immune Disturbances Do Not Involve IL-1ß but IL-6 and IL-10 Activation in Haemodialysis Patients.

Authors:  Christof Ulrich; Annegret Wilke; Nadja Schleicher; Matthias Girndt; Roman Fiedler
Journal:  Toxins (Basel)       Date:  2020-03-03       Impact factor: 4.546

7.  Non-invasive venous waveform analysis (NIVA) for volume assessment in patients undergoing hemodialysis: an observational study.

Authors:  Bret D Alvis; Monica Polcz; Merrick Miles; Donald Wright; Mohammad Shwetar; Phil Leisy; Rachel Forbes; Rachel Fissell; Jon Whitfield; Susan Eagle; Colleen Brophy; Kyle Hocking
Journal:  BMC Nephrol       Date:  2020-05-24       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.